PRODO ISLET MEDIA (PIM)®- Our media is a cGMP product and has been designed to increase the viability and purity of the cells, from the initial recovery to the stage where the islets are ready for study and experiments. Our media is capable of long-term culturing, of up to 21 days, without loss of purity and viability. The PIM® family of products has a Biological Master File with the Food and Drug Administration (IND-15016).
Welcome to Prodo Laboratories, Inc.
Prodo Laboratories is committed to providing advanced products, research and services to aid in the development of a cure for diabetes. We currently supply human islets to both the academic and corporate communities for their research related to diabetes. We pride ourselves on providing the highest quality islets, which we have been able to produce by using our proprietary media (PIM-Prodo Islet Media). Our media has been designed to increase the viablility and purity of the cells, from the initial recovery to the stage where the islets are ready for study and experiments. Please take a moment to view our product offerings and our testing services.
Prodo Labs will attend, speak and exhibit at the 14th World Congress of the International Pancreas and Islet Transplant Association meeting in Monterey, CA.
(Please visit our published papers section)!
Prodo Laboratories, Inc.'s mission is to deliver services and products to patients with diabetes and to the diabetes research community. It seeks to accomplish this goal by focusing its research and development activities on the improvement of the health and well being of all patients with diabetes.Our Motto: "Today, Not Tomorrow"
Prodo Labs provides high quality human islets for research as its primary service business by direct contracts with biotechnology and pharmaceutical companies utilizing them for in vitro and in vivo testing in the development of new drugs for diabetes or in the development of new insulin-producing cells for future transplants.
Prodo Laboratories, Inc was founded in Sept 2006 by David Scharp, MD to develop a biotechnology company that provides diabetes research services and products to both the academic and corporate diabetes research communities, as well as pursue its own research lines.